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Abstract
Background: FTY720, an immunomodulator derived from a fungal metabolite which reduces circulating
lymphocyte counts by increasing the homing of lymphocytes to the lymph nodes has recently gained interest in
stroke research. The aim of this study was to evaluate the protective efficacy of FTY720 in cerebral ischemia in two
different application paradigms and to gather first data on the effect of FTY720 on the rate of spontaneous
bacterial infections in experimental stroke.
Methods: Middle cerebral artery occlusion (MCAO) in C57BL/6 mice (strain J, groups of 10 animals) was performed
with two different durations of ischemia (90 min and 3 h) and FTY720 was applied 2 h after vessel occlusion to
study the impact of reperfusion on the protective potency of FTY720. Lesion size was determined by TTC staining.
Mice treated with FTY720 or vehicle were sacrificed 48 h after 90 min MCAO to determine the bacterial burden in
lung and blood.
Results: FTY720 1 mg/kg significantly reduced ischemic lesion size when administered 2 h after the onset of
MCAO for 3 h (45.4 ± 22.7 mm
3 vs. 84.7 ± 23.6 mm
3 in control mice, p = 0.001) and also when administered after
reperfusion, 2 h after the onset of MCAO for 90 min (31.1 ± 28.49 mm
3 vs. 69.6 ± 27.2 mm
3 in control mice, p =
0.013). Bacterial burden of lung homogenates 48 h after stroke did not increase in the group treated with the
immunomodulator FTY720 while there was no spontaneous bacteremia 48 h after MCAO in treated and untreated
animals.
Conclusions: Our results corroborate the experimental evidence of the protective effect of FTY720 seen in
different rodent stroke models. Interestingly, we found no increase in bacterial lung infections even though FTY720
strongly reduces the number of circulating leukocytes.
Background
Despite decades of basic and translational research,
there is still no pharmaceutical stroke treatment besides
thrombolysis which has been proven to be effective in
humans [1]. To promote the transition of scientific evi-
dence from animal studies on experimental stroke, the
Stroke Therapy Academic Industry Roundtable (STAIR)
has formulated a set of criteria for the conduct, report-
ing, and analysis of animal data which include the points
that drug candidates should be tried by different
research teams, in different stroke models, in different
animal species, and at different time points [2]. One
drug, which has recently gained a lot of interest and
already fulfils some of these criteria on the basis of the
current experimental evidence is the sphingosine
1-phosphate (S1P) analogue and immunomodulator
FTY720 (fingolimod).
FTY720 is phosphorylated to yield the biologically
active substance FTY720-phosphate by the ubiquitously
available sphingosine kinase-2 and to a lesser extent by
sphingosine kinase-1 [3]. FTY720-phosphate can activate
four of the five G protein-coupled S1P receptors known
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inflammatory responses by inducing the internalization
of the S1P1 receptor of lymphocytes and thus inhibits
the lymphocyte egress from the lymph node into the
systemic circulation [4], while the functional responses
of the lymphocytes remain relatively unaltered [5].
FTY720 has been shown to reduce lesion size and
improve neurological outcome after experimental stroke
in mice [6,7] and rats [7,8] with a therapeutic time win-
dow of up to four hours after the induction of ischemia
[7]. It has been shown to reduce brain damage after
stroke in models of transient [6-8] and permanent [7]
middle cerebral artery occlusion (MCAO) by reducing
the infiltration of neutrophils into the ischemic lesion
[6], attenuating the activation of microglia/macrophages
[6], reducing hallmarks of apoptotic cell death within
the lesion and activating survival pathways via Akt and
ERK phosphorylation [8] in the ischemic brain. The pro-
tective effect on lesion size was still present at 72 h after
MCAO [8] and FTY720-treated mice performed better
than controls in a behavioural test performed 15 days
after experimental stroke [7].
It is well known that cerebral ischemia has a profound
effect on the immune system, leading to an immunosup-
pression with reduced leukocyte counts and reactivity as
well as an atrophy of secondary lympoid tissues after
stroke [9]. Stroke patients are prone to infections, pre-
dominantly chest and urinary tract infections [10] and
pneumonia is the complication with the highest attribu-
table risk of death in the acute phase of stroke [11]. In
the MCAO model of cerebral ischemia, mice after
stroke showed higher rates of spontaneous bacterial
infections than control animals [12] and were more sus-
ceptible to infection after nasal inoculation of S. pneu-
moniae [13]. In this context, it is of great interest
whether FTY720 as an immunomodulatory substance
which reduces the number of circulating leukocytes,
especially T cells, is associated with a higher rate of
infectious complications. The aim of this study was to
evaluate the efficacy of FTY720 in two different applica-
tion paradigms before and after vessel recanalization in
large territorial infarctions and to gather first data on
the effect of FTY720 on the rate of spontaneous bacter-
ial infections in experimental stroke.
Methods
Animals and sample size calculation
Male C57BL/6 mice (10 weeks old, strain J) were used
in accordance with the National Institute of Health
Guide for the Care and Use of Laboratory Animals
(NIH Publications No. 80-23, revised 1996). The experi-
ments were approved by the local governmental authori-
ties (Regierungspraesidium Darmstadt, Germany,
approval number F143/34). In pilot experiments of the
two application paradigms for FTY720 tested in this
s t u d y ,w ef o u n dar e d u c t i o ni nl e s i o ns i z eo fa p p r o x i -
mately 50% with a standard deviation of 0.33 to 0.5 of
the lesion size leading to an effect size (Cohen’sd )o f
1.697 [13]. To detect this effect size with an alpha level
of 0.05 and a statistical power of 0.9, nine animals per
group were needed. 10 animals per group were rando-
mized to receive either FTY720 or vehicle.
Middle cerebral artery occlusion
The operator was blinded to the treatment status of the
animals. Transient MCAO was performed as described
previously [6] in groups of 10 vs. 10 animals per appli-
cation paradigm. Mice were anaesthetized with 1.5%
isoflurane (Forene; Abbott, Wiesbaden, Germany) and
0.1 mg/kg buprenorphine (Temgesic; Essex Pharma,
Munich, Germany) under spontaneous respiration. Focal
cerebral ischemia was induced by introducing a silicone-
coated 7-0 monofilament until it occluded the ostium of
the right MCA. Regional cerebral blood flow was moni-
tored by laser Doppler flowmetry (PF5010, Perimed, Jär-
fälla, Sweden) to confirm vessel occlusion. The filament
was withdrawn after the indicated time points, i.e. 3 h
or 90 min, to allow reperfusion of the ischemic hemi-
sphere. Animals were sacrificed at 24 h, 36 h or 48 h
after assessment of their global neurological functions
with a 5-point neuroscore (0 = no deficit, 1 = failure to
extend left paw, 2 = circling to the left, 3 = falling to
the left, 4 = unable to walk spontaneously, 5 = death).
All animals that showed a drop of the Doppler flow
below 40% of the initial value and a neurological deficit
(neuroscore ≥ 1) were included in the analysis.
Dosing and administration of FTY720
FTY720 (Cayman Chemicals Europe, Tallinn, Estonia)
was dissolved in 0.9% NaCl at a final concentration of
125 μg/ml yielding a clear liquid and 200 - 250 μl were
injected intraperitoneally 2 h after the onset of cerebral
ischemia. Control animals received the corresponding
volume of 0.9% NaCl i.p. Syringes were prepared by an
allocator and administered by the operator in a blinded
fashion.
Assessment of ischemic lesion volume
Twenty-four hours after the onset of ischemia, brains
were removed and cut into sections of 1 mm thickness
using a mouse brain matrix (RBM 2000C; ASI Instru-
ments, Warren, Mich; USA). The brain sections were
stained in 2% (w/v) 2,3,5-triphenyltetrazolium chloride
(TTC, Merck, Darmstadt, Germany) in phosphate buffer
at 37°C for 10 minutes. Brain slices were digitized and
infarct volumes were measured by an observer who was
blinded to the treatment conditions with the National
Institutes of Health Image J software analysing four
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correction for edema was established by multiplying the
infarct section volume by the ratio of the contralateral
to the ischemic hemisphere section volume.
Microbiological Analyses
Mice were subjected to 90 min MCAO and substance
application at the onset of reperfusion. Thereafter, mice
were returned to their cages for 24 h, 36 h and 48 h to
observe whether they developed spontaneous bacterial
infections. Only mice that showed a neurological deficit
after 24 h were used for further analyses. 24 h, 36 h and
48 h after the induction of cerebral ischemia, the
anesthetized mice were washed in 70% alcohol under
sterile conditions. Lungs were removed and homoge-
nized in sterile phosphate-buffered solution. For the
determination of the bacterial load, Blood was drawn
from the heart into an EDTA collection tube and 100 μl
were serially diluted and plated onto blood and choco-
late agar for anaerobic and aerobic incubation, respec-
tively. 100 μl of lung homogenate were serially diluted
and plated onto appropriate agar as described above.
Colonies were counted after incubation for 48 h at 37°C.
Lung infection was defined as any bacterial growth from
the sterilely collected lung samples. Status of lung infec-
tion was categorized into four groups (no infection,
<5.000 CFU/ml, >50.000 CFU/ml and death). Accord-
ingly, these groups were further dichotomized into
“moderate or no infection” and “severe infection or
death”.
Statistical analysis
Graph Pad Prism 4 (Graph Pad Software Inc., La Jolla,
CA, USA) was used for statistical analysis. Results are
given as mean ± SD and graphically presented as a box
and whiskers plot depicting the mean, extreme values
and the 25 - 75 interquartile range. Statistical signifi-
cance was assessed with an unpaired, two-tailed stu-
dent’s t-test and a Mann-Whitney-Test where indicated.
Statistical significance between the dichotomized infec-
tion rates in FTY- and vehicle-treated animals was
tested with a two-sided chi-square test.
Results
FTY720 significantly reduces lesion size in large territorial
infarctions
Application of FTY720 (1 mg/kg i.p.) 2 h after the onset
of cerebral ischemia significantly reduced ischemic
lesion size in mice subjected to three hours MCAO
(45.4 ± 22.7 mm
3 vs. 84.7 ± 23.6 mm
3 in control mice,
p = 0.001, n = 10 vs. 10, Figure 1A). Functionally, this
was reflected by a less severe neurological deficit of the
FTY720-treated animals (mean neuroscore value 2,
range 1 - 3 vs. mean 3, range 2 - 4 in control mice, p =
0.005, Figure 1B). None of the animals died during the
operation and during the 24 h observation time.
FTY720 is also protective when administered after
reperfusion
In a second experimental paradigm, we administered
FTY720 (1 mg/kg i.p.) 2 h after the onset of MCAO for
90 minutes, hence after the induction of reperfusion.
Even under these conditions, FTY720 significantly
halved the ischemic lesion size at 24 h (31.1 ± 28.5 mm
3
vs. 69.6 ± 27.2 mm
3 in control mice, p = 0.013, n = 7 vs.
10, Figure 2A), but there was only a tendency towards a
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Figure 1 A: FTY720 reduces ischemic lesion size in large
territorial infarctions. MCAO was performed for 3 h. FTY720 or
vehicle were administered 2 h after the induction of cerebral
ischemia (n = 10 in both groups). Data are depicted as box and
whiskers plots showing the 25 to 75 percentile and the extreme
values. Statistical significance was assessed with students unpaired t-
test. ** p < 0.01. B: The functional neurological status of the mice
was tested with a 5-point neuroscore after 24 h. Medians are given
and statistical significance was tested with a Mann-Whitney test. **
p < 0.01.
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(mean neuroscore value 2, range 1-4 vs. mean 2, range
1-4 in control animals, p = 0.81, Figure 2B). Three mice
of the FTY720-treated group were excluded (1 did not
show a neurological deficit, 1 developed SAH and 1
died during the induction of anesthesia).
FTY720 does not increase the rate of bacterial infections
at48 h after MCAO
We randomized 3 vs. 3 animals to vehicle or FTY720
treatment. In untreated animals, there was an excess
death rate, which prompted us to include more
animals in this group a posteriori (10 mice in total) to
obtain a reasonable number for microbiological analy-
sis. All of the 5 animals that died in the control group
did so between the 36 h and the 48 h observation time
points. But also in the surviving 5 animals, the rate of
severe lung infections >50.000 CFU/ml was consider-
ably high while none of the FTY720-treated animals
died during the observation period or showed a severe
infection (Figure 3). Dichotomized into “moderate or
no infection” and “severe infection or death”,w ef o u n d
significantly less severe pulmonary infections in the
FTY720-treated compared to the vehicle-treated group
(Table 1, p = 0.033). We did not detect bacteremia in
any of the mice (data not shown) and we did not
detect lung infections in mice whose lungs were
sampled after shorter time spans (24 h and 36 h, data
not shown).
Contingency table showing the number of mice in
each group after the degree of infection was dichoto-
mized into “moderate or nor infection” and “severe
infection or death”. Statistical significance was assayed
with a Chi-square test, p = 0.033.
Discussion
Adding to the considerable body of experimental evi-
dence on the protective effect of FTY720 in stroke [6-8],
our experiments show that FTY720 is also protective in
large hemispheric infarctions within a therapeutic time
window that is achievable in patient care. Even if admi-
nistered after the critical time point of reperfusion, it
still leads to a significant reduction in ischemic lesion
size.
After two successful phase III trials [14,15] FTY720
has been approved as the first orally available drug to
treat relapsing-remitting multiple sclerosis by the FDA
in 2010. In over 1200 patients, FTY720 was generally
well tolerated and did not lead to a significantly elevated
rate of infections, but two cases of severe viral infections
occurred in the verum groups. The highest dose in the
aforementioned trials was 1.25 mg (approx. 0.02 mg/kg)
administered as a chronic daily dose, which is fiftyfold
lower than the dose of 1 mg/kg required for a protective
effect in experimental stroke in mice [7]. The highest
dose reported in humans so far was 5 mg administered
on a daily basis [16] and dosing was limited by the S1P
receptor-mediated bradycardia which occurs within
hours after FTY720 intake.
FTY720 leads to a reduction of circulating immune
cells, especially T cells, as we have shown previously [6].
At 1 mg/kg, the number of circulating neutrophils is
also reduced [[17], and Pfeilschifter W. unpublished
observations]. Especially in consideration of the well-
described phenomenon of stroke-induced immunosup-
pression (cerebral injury induced immune deficiency
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Figure 2 A: FTY720 reduces ischemic lesion size when
administered after reperfusion. MCAO was performed for 90 min
and FTY720 (n = 10) or vehicle (n = 7) were applied 2 h after vessel
occlusion. Data are depicted as box and whiskers plots showing the
25 to 75 percentile and the extreme values. Statistical significance
was assessed with student’s unpaired, two-tailed t-test. * p < 0.05. B:
The functional neurological status of the mice was tested with a 5-
point neuroscore after 24 h. Medians are given and statistical
significance was tested with a Mann-Whitney test. n.s. = not
significant.
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the influence of FTY720-treatment on the rate of
stroke-associated infections because they constitute an
important factor that modulates the outcome of stroke
patients [11]. We observed varying degrees of bacterial
colonization in the lungs of mice 48 h after stroke and
only very few lung homogenate samples remained sterile
during incubation. This is in accordance with an earlier
study [12], corroborating the hypothesis that mice after
stroke are prone to bacterial lung infections. However,
in contrast to the aforementioned study, which docu-
mented the first cases of bacterial lung infection after 12
h with a constant rise of the incidence of infection and
bacterial load over the following 72 h as well as blood
stream infections beginning at 24 h after stroke, we
neither found bacteremia at all after 48 h nor lung
infections at the 24 h and 36 h time points. There are
several possible explanations for this divergence. Since
both experiments detected spontaneous bacterial infec-
tions, the local spectrum of bacteria in the respective
animal care facilities might be one determinant. Since
t h ed e g r e eo fC I D Si sc r i t i c a l l yd e t e r m i n e db yt h e
size of the brain lesion both in humans [19] and in
mice [20], differences in ischemic lesion size might also
explain differences in the susceptibility to bacterial
infections. An analysis of the results of our microbiolo-
gical examination dichotomized in moderate and severe
pulmonary infections even showed a significantly lower
rate of severe infections in FTY720-treated animals
compared to controls. One possible explanation is that
given the immunosuppressive effect of acute brain
lesions, the reduction of lesion size achieved by FTY720
might outweigh its immunomodulatory effect. Nonethe-
less, given the small number of animals, these results
have to be interpreted with utmost care.
Conclusions
While corroborating the protective effect of FTY720 in
stroke in various rodent models and modes of applica-
tion, our data also suggest that FTY720 does not further
aggravate stroke-induced immune depression to a clini-
cally relevant degree as evaluated microbiologically.
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